Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Repisalud
Publication Artículo científico (JournalArticle)

Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes

  • Cedena, M Teresa
  • Rapado, Inmaculada
  • Santos-Lozano, Alejandro
  • Ayala, Rosa
  • Onecha, Esther
  • Abaigar, María
  • Such, Esperanza
  • Ramos, Fernando
  • Cervera, José
  • Díez-Campelo, María
  • Sanz, Guillermo
  • Rivas, Jesús Hernández
  • Lucía, Alejandro
  • Martinez-Lopez, Joaquin
We evaluated the association of mutations in 34 candidate genes and response to azacitidine in 84 patients with myelodysplastic syndrome (MDS), with 217 somatic mutations identified by next-generation sequencing. Most patients (93%) had ≥1 mutation (mean=2.6/patient). The overall response rate to azacitidine was 42%. No clinical characteristic was associated with response to azacitidine. However, total number of mutations/patient was negatively associated with overall drug response (odds ratio [OR]: 0.56, 95% confidence interval [CI]: 0.33-0.94; p=0.028), and a positive association was found for having ≥1 mutation in a DNA methylation-related gene: TET2, DNMT3A, IDH1 and/or IDH2 (OR: 4.76, 95%CI: 1.31-17.27; p=0.017). Mutations in TP53 (hazard ratio [HR]: 3.88; 95%CI: 1.94-7.75) and EZH2 (HR: 2.50; 95%CI: 1.23-5.09) were associated with shorter overall survival. Meta-analysis of 6 studies plus present data (n=815 patients) allowed assessment of the association of drug response with mutations in 9 candidate genes: ASXL1, CBL, EZH2, SF3B1, SRSF2, TET2, DNMT3A, IDH1/2 and TP53. TET2 mutations predicted a more favorable drug response compared with 'wild-type' peers (pooled OR: 1.67, 95%CI: 1.14-2.44; p=0.01). In conclusion, mutations in the DNA methylation pathway, especially TET2 mutations, and low number of total mutations are associated with a better response to azacitidine.
Repisalud
Publication Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martinez-Sanchez, Pilar
  • Cedena, Teresa
  • Pratcorona, Marta
  • Oteyza, Jaime Perez
  • Herrera, Pilar
  • Barragan, Eva
  • Montesinos, Pau
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu, Josep
  • Gallardo, Miguel
  • Martinez-Lopez, Joaquin
  • Ayala, Rosa
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10-4 for single nucleotide variants and 10-5 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.
Docta Complutense
Publication Artículo científico (JournalArticle)

Improving the prediction of acute myeloid leukaemia outcomes by complementing mutational profiling with ex vivo chemosensitivity

  • Onecha, Esther
  • Ruiz‐Heredia, Yanira
  • Martínez‐Cuadrón, David
  • Barragán, Eva
  • Martínez Sánchez, María Del Pilar
  • Linares Gómez, María
  • Rapado, Inmaculada
  • Perez‐Oteyza, Jaime
  • Magro, Elena
  • Herrera, Pilar
  • Rojas, José Luis
  • Gorrochategui, Julián
  • Villoria, Jesús
  • Boluda, Blanca
  • Sargas, Claudia
  • Ballesteros, Joan
  • Montesinos, Pau
  • Martínez López, Joaquín
  • Ayala Díaz, Rosa María
Refractoriness to induction therapy and relapse after complete remission are the leading causes of death in patients with acute myeloid leukaemia (AML). This study focussed on the prediction of response to standard induction therapy and outcome of patients with AML using a combined strategy of mutational profiling by next-generation sequencing (NGS, n = 190) and ex vivo PharmaFlow testing (n = 74) for the 10 most widely used drugs for AML induction therapy, in a cohort of adult patients uniformly treated according to Spanish PETHEMA guidelines. We identified an adverse mutational profile (EZH2, KMT2A, U2AF1 and/or TP53 mutations) that carries a greater risk of death [hazard ratio (HR): 3 29, P < 0 0001]. A high correlation was found between the ex vivo PharmaFlow results and clinical induction response (69%). Clinical correlation analysis showed that the pattern of multiresistance revealed by ex vivo PharmaFlow identified patients with a high risk of death (HR: 2 58). Patients with mutation status also ran a high risk (HR 4 19), and the risk was increased further in patients with both adverse profiles (HR 4 82). We have developed a new score based on NGS and ex vivo drug testing for AML patients that improves upon current prognostic risk stratification and allows clinicians to tailor treatments to minimise drug resistance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia

  • Onecha, Esther
  • Linares, Maria
  • Rapado, Inmaculada
  • Ruiz-Heredia, Yanira
  • Martínez Sánchez, Pilar|||0000-0002-7334-140X
  • Cedena, Teresa
  • Pratcorona, Marta|||0000-0001-6375-596X
  • Oteyza, Jaime Perez
  • Herrera, Pilar|||0000-0002-4118-7110
  • Barragán, Eva
  • Montesinos, Pau|||0000-0002-3275-5593
  • Vela, Jose Antonio Garcia
  • Magro, Elena
  • Anguita, Eduardo|||0000-0003-1386-4943
  • Figuera, Angela
  • Riaza, Rosalia
  • Martinez-Barranco, Pilar
  • Sanchez-Vega, Beatriz
  • Nomdedeu Guinot, Jose Francisco|||0000-0003-3399-346X
  • Gallardo, Miguel
  • Martínez-López, Joaquín|||0000-0001-7908-0063
  • Ayala, Rosa|||0000-0002-2699-8353
A high proportion of patients with acute myeloid leukemia who achieve minimal residual disease negative status ultimately relapse because a fraction of pathological clones remains undetected by standard methods. We designed and validated a high-throughput sequencing method for minimal residual disease assessment of cell clonotypes with mutations of NPM1, IDH1/2 and/or FLT3-single nucleotide variants. For clinical validation, 106 follow-up samples from 63 patients in complete remission were studied by sequencing, evaluating the level of mutations detected at diagnosis. The predictive value of minimal residual disease status by sequencing, multiparameter flow cytometry, or quantitative polymerase chain reaction analysis was determined by survival analysis. The sequencing method achieved a sensitivity of 10 for single nucleotide variants and 10 for insertions/deletions and could be used in acute myeloid leukemia patients who carry any mutation (86% in our diagnostic data set). Sequencing-determined minimal residual disease positive status was associated with lower disease-free survival (hazard ratio 3.4, P=0.005) and lower overall survival (hazard ratio 4.2, P<0.001). Multivariate analysis showed that minimal residual disease positive status determined by sequencing was an independent factor associated with risk of death (hazard ratio 4.54, P=0.005) and the only independent factor conferring risk of relapse (hazard ratio 3.76, P=0.012). This sequencing-based method simplifies and standardizes minimal residual disease evaluation, with high applicability in acute myeloid leukemia. It is also an improvement upon flow cytometry- and quantitative polymerase chain reaction-based prediction of outcomes of patients with acute myeloid leukemia and could be incorporated in clinical settings and clinical trials.